← Back to Screener
Krystal Biotech, Inc. Common Stock (KRYS)
Price$276.50
Favorite Metrics
Price vs S&P 500 (26W)42.36%
Price vs S&P 500 (4W)-0.54%
Market Capitalization$8.02B
P/E Ratio (Annual)39.13x
All Metrics
P/CF (Annual)39.91x
Book Value / Share (Quarterly)$41.78
P/TBV (Annual)5.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$6.47
Price vs S&P 500 (YTD)7.08%
Gross Margin (TTM)94.08%
Net Profit Margin (TTM)52.64%
EPS (TTM)$6.84
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$6.84
EPS (Annual)$6.84
ROI (Annual)16.80%
Gross Margin (Annual)94.08%
Cash / Share (Quarterly)$28.36
P/E Basic Excl Extra (TTM)39.13x
Revenue Growth QoQ (YoY)17.52%
P/E Normalized (Annual)39.13x
ROA (Last FY)15.36%
Revenue Growth TTM (YoY)33.95%
EBITD / Share (TTM)$5.57
ROE (5Y Avg)-2.18%
Operating Margin (TTM)41.41%
Cash Flow / Share (Annual)$6.47
P/B Ratio6.57x
P/B Ratio (Quarterly)5.86x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)19.32x
Net Interest Coverage (TTM)-52.52x
ROA (TTM)17.12%
EPS Growth QoQ (YoY)11.66%
EV / EBITDA (TTM)45.07x
EPS Incl Extra (Annual)$6.84
Current Ratio (Annual)9.95x
Quick Ratio (Quarterly)9.28x
3-Month Avg Trading Volume0.30M
52-Week Price Return66.49%
EV / Free Cash Flow (Annual)39.80x
P/E Incl Extra (TTM)39.13x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$26.81
P/S Ratio (Annual)20.60x
Asset Turnover (Annual)0.29x
52-Week High$298.30
EPS Excl Extra (Annual)$6.84
CapEx CAGR (5Y)-4.24%
Tangible BV CAGR (5Y)60.21%
26-Week Price Return51.10%
Quick Ratio (Annual)9.28x
13-Week Price Return-6.02%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.95x
Enterprise Value$7,519.454
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)23.03%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)48.69%
Cash / Share (Annual)$28.36
3-Month Return Std Dev37.95%
Net Income / Employee (TTM)$1
ROE (Last FY)16.80%
Net Interest Coverage (Annual)-9.83x
EPS Basic Excl Extra (Annual)$6.84
P/FCF (TTM)42.43x
Receivables Turnover (TTM)3.35x
EV / Free Cash Flow (TTM)39.80x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$6.84
ROI (TTM)18.69%
P/S Ratio (TTM)20.60x
Revenue / Share (Annual)$12.99
Tangible BV / Share (Annual)$20.27
Forward P/E36.19x
Price vs S&P 500 (52W)31.40%
P/E Ratio (TTM)39.13x
EPS Growth TTM (YoY)129.21%
Year-to-Date Return11.22%
5-Day Price Return2.54%
EPS Normalized (Annual)$6.84
ROA (5Y Avg)-2.21%
Net Profit Margin (Annual)52.64%
Month-to-Date Return6.15%
Cash Flow / Share (TTM)$-0.95
EBITD / Share (Annual)$5.58
Operating Margin (Annual)41.45%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)39.91x
ROI (5Y Avg)-2.18%
P/E Excl Extra (TTM)39.13x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$6.84
P/TBV (Quarterly)3.84x
P/B Ratio (Annual)5.86x
Inventory Turnover (TTM)0.69x
Pretax Margin (TTM)48.69%
Book Value / Share (Annual)$41.78
Price vs S&P 500 (13W)-8.89%
Beta0.53x
P/FCF (Annual)42.43x
Revenue / Share (TTM)$12.84
ROE (TTM)18.69%
52-Week Low$122.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.33
4.35
4.28
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KRYSKrystal Biotech, Inc. Common Stock | 20.60x | 33.95% | 94.08% | — | $276.50 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Krystal Biotech is a commercial-stage biotechnology company developing genetic medicines for diseases with high unmet medical needs using its proprietary HSV-1-based gene therapy platform. The company commercializes VYJUVEK, its lead therapeutic product, across the United States, European Union, and Japan. Krystal Biotech leverages its platform to create vectors that deliver therapeutic genes to target cells with exclusive rights to develop, manufacture, and commercialize VYJUVEK globally.